Expertise in
15
conditions

Dr. Yousef N. Zakharia

Oncology
Mayo Clinic Hospital In Arizona
5777 E Mayo Blvd, 
Phoenix, AZ 
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
Mayo Clinic Hospital In Arizona
5777 E Mayo Blvd, 
Phoenix, AZ 

Overview

Yousef Zakharia is an Oncologist practicing medicine in Phoenix, Arizona.

Dr. Zakharia is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Melanoma, and Orchiectomy.

He is actively involved in clinical research, co-authoring 148 peer reviewed articles and participating in 17 clinical trials. Dr. Zakharia is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in GA

Hospital Affiliations

Mayo Clinic Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EMI Health
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 14 Less Insurance Carriers -

Locations

Mayo Clinic Hospital In Arizona
5777 E Mayo Blvd, Phoenix, AZ 85054
Other Locations
University of Iowa Stead Family Children's Hospital
200 Hawkins Dr, Iowa City, IA 52242

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies
Enrollment Status: Completed
Publish Date: July 06, 2026
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Pembrolizumab
Study Phase: Phase 2
A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma
A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: May 29, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Therapeutic Trial for Safety and Preliminary Efficacy of the Combination of Axitinib and Seleniomethionine (SLM) for Adult Patients With Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
A Therapeutic Trial for Safety and Preliminary Efficacy of the Combination of Axitinib and Seleniomethionine (SLM) for Adult Patients With Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
Enrollment Status: Completed
Publish Date: May 06, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Cabozantinib and Pembrolizumab as a Front-line Therapy for Advanced Metastatic Melanoma
Cabozantinib and Pembrolizumab as a Front-line Therapy for Advanced Metastatic Melanoma
Enrollment Status: Terminated
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: Cabozantinib, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Phase I/II Study of Seleno-L Methionine (SLM) in Sequential Combination With Fixed Doses and Schedules of Axitinib and Pembrolizumab (SAP) in Locally Advanced and Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
Phase I/II Study of Seleno-L Methionine (SLM) in Sequential Combination With Fixed Doses and Schedules of Axitinib and Pembrolizumab (SAP) in Locally Advanced and Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Clinical Accuracy Assessment of 68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence
Clinical Accuracy Assessment of 68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence
Enrollment Status: Completed
Publish Date: April 17, 2025
Intervention Type: Drug
Study Drug: Ga-68 Prostate-Specific Membrane Antigen-HBED-CC PET
Study Phase: Phase 2/Phase 3
Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: Big Ten Cancer Research Consortium BTCRC-GU15-023
Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: Big Ten Cancer Research Consortium BTCRC-GU15-023
Enrollment Status: Terminated
Publish Date: November 27, 2024
Intervention Type: Radiation, Drug
Study Phase: Phase 1/Phase 2
68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence
68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence
Enrollment Status: Completed
Publish Date: July 12, 2024
Intervention Type: Drug
Study Drug: Ga-68 PSMA-HBED-CC PET
Study Phase: Phase 2/Phase 3
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
View 9 Less Clinical Trials

148 Total Publications

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
Journal: The New England journal of medicine
Published: July 22, 2026
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

AZ - Cancer

5777 E Mayo Blvd, 
Phoenix, AZ 
 (0.1 miles away)
480-933-6836
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tanios Bekaii-Saab is an Oncologist practicing medicine in Phoenix, Arizona. Dr. Bekaii-Saab is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Ductal Adenocarcinoma, and Pancreatectomy. Dr. Bekaii-Saab is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

AZ - Cancer

5777 E Mayo Blvd, 
Phoenix, AZ 
 (0.1 miles away)
480-933-6836
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mitesh Borad is an Oncologist practicing medicine in Phoenix, Arizona. Dr. Borad is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Gallbladder Cancer, Liver Cancer, and Tissue Biopsy.

Expertise in
32
conditions
Dr. Allison C. Rosenthal
Hematology | Oncology
Expertise in
32
conditions
Dr. Allison C. Rosenthal
Hematology | Oncology
Referral may be required

AZ - Cancer

5777 E Mayo Blvd, 
Phoenix, AZ 
 (0.1 miles away)
480-933-6836
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Allison Rosenthal is a Hematologist and an Oncologist practicing medicine in Phoenix, Arizona. Dr. Rosenthal is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Yousef N. Zakharia

How do I make an appointment with Dr. Yousef N. Zakharia?

You can book an appointment with Dr. Yousef N. Zakharia by calling their office at 480-342-4800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Yousef N. Zakharia a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Yousef N. Zakharia is classified as an Elite expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Yousef N. Zakharia specialize in?

While Dr. Yousef N. Zakharia is a Oncology, they have specific expertise in Renal Cell Carcinoma (RCC), Urothelial Cancer, and Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Yousef N. Zakharia participate in research or clinical trials?

Yes. Dr. Yousef N. Zakharia has published 148 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Dr. Yousef N. Zakharia's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Yousef N. Zakharia accept my insurance?

Dr. Yousef N. Zakharia accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 480-342-4800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zakharia's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile